Page last updated: 2024-09-05

erlotinib hydrochloride and Diffuse Parenchymal Lung Disease

erlotinib hydrochloride has been researched along with Diffuse Parenchymal Lung Disease in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (18.18)	29.6817
2010's	43 (78.18)	24.3611
2020's	2 (3.64)	2.80

Authors

Authors	Studies
Chen, YY; Li, MH; Tang, XJ	1
Adli, M; Aliyev, A; Besiroglu, M; Simsek, M; Turk, HM	1
Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K	1
Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kuwae, Y; Matsumoto, Y; Mitsuoka, S; Sawa, K; Suzumura, T; Watanabe, T; Yamamoto, N; Yoshimoto, N; Yoshimura, N	1
Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K	1
Hsu, WH; Loong, HH; Mok, TS; Yang, JC	1
Ahsmann, EJ; Eshuis, M; van Egmond, NH	1
Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N	1
Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H	1
Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK	1
Liu, Z; Shi, L; Tang, J; Tong, L	1
Qi, WX; Shen, Z; Sun, YJ; Yao, Y	1
Arakawa, H; Fukuoka, M; Harada, R; Johkoh, T; Kudoh, S; Kusumoto, M; Sakai, F; Ueda, M	1
Akiyama, Y; Fujita, K; Hirose, T; Kusumoto, S; Nakashima, M; Sasaki, Y; Shirai, T; Sugiyama, T	1
Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N	1
Bugés, C; Capdevila, L; Carcereny, E; Cardona, AF; Cros, S; Moran, T; Reguart, N; Rosell, R	1
Abdel-Rahman, O; Elhalawani, H	1
Aprile, G; Cardellino, GG; Foltran, L; Macerelli, M; Mazzer, M	1
Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A	1
Chayahara, N; Imamura, Y; Kiyota, N; Kotake, T; Minami, H; Mukohara, T; Nishimura, M; Saito, K; Saito, Y; Takenaka, K; Toyoda, M; Tsuji, A	1
Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA	1
Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S	1
Grünberg, K; Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF	1
Camidge, DR; Erickson, TM; Koeppe, JR; Miller, YE; Stuart, RW	1
Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N	1
Hammersley, JR; Kanjwal, S; Taj, A	1
Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S	1
Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H	1
Choi, PJ; Kim, KN; Lee, KN; Lee, SK; Roh, MS; Son, C; Um, SJ; Yang, DK	1
Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC	1
Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M	1
Chang, CY; Chang, SC; Chen, CY; Yu, CJ	1
Jones, SJ; Milenkova, T	1
Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M	1
Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY	1
Grazioso Russi, E; Numico, G; Silvestris, N	1
Bar-Sela, G; Haim, N; Nasrallah, H	1
Dallas, JL; Jantz, MA; Kaye, FJ; Lightsey, JL; Sonntag, C	1
Dallas, J; Jantz, MA; Kaye, FJ	1
Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS	1
Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H	1
Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM	1
Daw, HA; Peerzada, MM; Spiro, TP	1
Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y	1
Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N	1
Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H	1
Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z	1
Gao, G; Ren, S; Wu, X; Zhou, C	1
Matsuo, K; Takada, Y	1
Baldwin, PD; Lundberg, AS; Tammaro, KA	1
Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K	1
Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY	1
Brun, L; Colin, G; Copin, MC; Lafitte, JJ; Makris, D; Marquette, CH; Scherpereel, A	1
Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C	1
Azzoli, CG; Ginsberg, MS; Kris, MG; Liu, V; Miller, VA; Travis, W; White, DA; Zakowski, MF	1

Reviews

10 review(s) available for erlotinib hydrochloride and Diffuse Parenchymal Lung Disease

Article	Year
Overview of current systemic management of EGFR-mutant NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:suppl_1 Topics: Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Molecular Targeted Therapy; Mucositis; Paronychia; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2018
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis	2014
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:1 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors	2015
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future oncology (London, England), 2015, Volume: 11, Issue:7 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk	2015
Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review. Tumori, 2015, Jul-24, Volume: 101, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autopsy; Critical Care; Diagnosis, Differential; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed	2015
Advances in EGFR-directed therapy in head and neck cancer. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis	2011
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 75, Issue:3 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines	2012
Pulmonary toxicities of tyrosine kinase inhibitors. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:11 Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines	2011
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2012
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review. International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:10 Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012

Trials

4 trial(s) available for erlotinib hydrochloride and Diffuse Parenchymal Lung Disease

Article	Year
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). Clinical lung cancer, 2013, Volume: 14, Issue:4 Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry	2013
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer science, 2014, Volume: 105, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Treatment Outcome	2014
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2 Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate	2010
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2007

Other Studies

41 other study(ies) available for erlotinib hydrochloride and Diffuse Parenchymal Lung Disease

Article	Year
[Erlotinib-induced interstitial pneumonia: a case report]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2021, 05-23, Volume: 43, Issue:5 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors	2021
Successful retreatment with erlotinib after erlotinib-related interstitial lung disease. Tumori, 2021, Volume: 107, Issue:6 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Remission Induction; Retreatment	2021
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs. Clinical lung cancer, 2017, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. Internal medicine (Tokyo, Japan), 2017, Sep-01, Volume: 56, Issue:17 Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors	2017
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA oncology, 2018, 08-01, Volume: 4, Issue:8 Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Nivolumab; Prognosis	2018
[Fatal interstitial lung disease associated with erlotinib use]. Nederlands tijdschrift voor geneeskunde, 2013, Volume: 157, Issue:7 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2013
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2013
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma. Journal of the Chinese Medical Association : JCMA, 2013, Volume: 76, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2013
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. Clinical lung cancer, 2014, Volume: 15, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Tomography, X-Ray Computed	2014
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2014
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient. Clinical lung cancer, 2015, Volume: 16, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; White People	2015
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. PloS one, 2015, Volume: 10, Issue:8 Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid	2015
The combination of HLA-B15:01 and DRB115:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Frequency; HLA-B27 Antigen; HLA-DRB1 Chains; Humans; Infusions, Intravenous; Japan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Young Adult	2016
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. Clinical lung cancer, 2017, Volume: 18, Issue:1 Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment	2017
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2017
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:9 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed	2008
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:11 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Chronic Disease; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Female; HIV; HIV Infections; Humans; Lung Diseases, Interstitial; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines	2008
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:8 Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2009
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung. American journal of therapeutics, 2011, Volume: 18, Issue:1 Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed	2011
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4 Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors	2010
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. The clinical respiratory journal, 2009, Volume: 3, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis	2009
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2010
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2010
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines	2010
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma. Pancreas, 2011, Volume: 40, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines	2011
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report. BMC cancer, 2010, Dec-31, Volume: 10 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2010
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines	2012
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:6 Topics: Adenocarcinoma; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Retreatment; Treatment Outcome	2011
Erlotinib or gefitinib for non-small-cell lung cancer. The New England journal of medicine, 2011, 06-16, Volume: 364, Issue:24 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2011
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:7 Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic	2011
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis	2011
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:8 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult	2012
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration; international review of thoracic diseases, 2012, Volume: 84, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2012
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:8 Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed	2012
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease. The Keio journal of medicine, 2012, Volume: 61, Issue:4 Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha	2012
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed	2005
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Japanese journal of clinical oncology, 2006, Volume: 36, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film	2006
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC cancer, 2007, Aug-05, Volume: 7 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Tomography, X-Ray Computed	2007
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography	2007
Pulmonary toxicity associated with erlotinib. Chest, 2007, Volume: 132, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2007